-
Nuvation Bio NYSE:NUVB Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Location: 1500 Broadway, New York, NY, 10036, United States | Website: https://www.nuvationbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
318.7M
Cash
461.7M
Avg Qtr Burn
-39.33M
Short % of Float
16.47%
Insider Ownership
19.12%
Institutional Own.
61.77%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Taletrectinib (ROS1 inhibitor) Details Cancer, Non-small cell lung carcinoma Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
Safusidenib Details Cancer, High-grade Glioma
| Phase 2 Data readout | |
NUV-1511 Details Solid tumor/s | Phase 1/2 Data readout | |
NUV-868 +enzalutamide Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Phase 1b Data readout | |
NUV-868 +olaparib Details Solid tumor/s, Cancer, Ovarian cancer, Pancreatic cancer, Triple-negative breast cancer , Castration-resistant prostate cancer | Phase 1b Update | |
NUV-868 (BD2-Selective BETi) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
NUV-422 (CDK inhibitor) Details High-grade Glioma
, Solid tumor/s, Cancer, Prostate cancer, Breast cancer, Castration-resistant prostate cancer, Metastatic breast cancer | Failed Discontinued |